Multiple System Atrophy Market Size was approximately USD 125 million in 2022

"With the expected launch of emerging therapies, the multiple system atrophy market is expected to show positive growth in the forecast period in the 7MM. Moreover, increased awareness of MSA has amplified drug research and development"

The Multiple System Atrophy market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Multiple System Atrophy market size from 2019 to 2032. The report also covers current Multiple System Atrophy treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Key takeaways from the Multiple System Atrophy Market Research Report

• As per DelveInsight analysis, the multiple system atrophy market size in the 7MM was approximately USD 125 million in 2021.

• In 2022, the market size of MSA was highest in the US among the 7MM, accounting for approximately USD 84 million, which is further expected to increase by 2032.

• The leading Multiple System Atrophy Market Companies include H Lundbeck A/S, Theravance Biopharma, Brain Neurotherapy Bio, Inc., Jonis Pharmaceuticals, Inc., Alterity Therapeutics, and others.

• Promising Multiple System Atrophy Pipeline Therapies include Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, and others.

For more insights into the Multiple System Atrophy Market Landscape, visit Multiple System Atrophy Market Therapeutics Landscape @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple System Atrophy Overview
Multiple system atrophy (MSA) is a rare, rapidly progressing, fatal neurodegenerative disorder of uncertain etiology that is clinically characterized by a variable combination of Parkinsonism, cerebellar impairment, and autonomic and motor dysfunctions. Depending on the predominant clinical phenotype, the disease is sub-classified into a parkinsonian variant (MSA-P) associated with SND, a cerebellar (MSA-C) variant with OPCA with predominant cerebellar features, and a combination of both forms referred to as "mixed" MSA.

Multiple System Atrophy Epidemiology Segmentation in the 7MM
• Multiple System Atrophy Diagnosed Prevalent Cases
• Multiple System Atrophy Gender-specific Diagnosed Prevalent Cases
• Multiple System Atrophy Age-specific Diagnosed Prevalent Cases
• Multiple System Atrophy Type-specific Diagnosed Prevalent Cases

To know more information of the Multiple System Atrophy Epidemiology Segmentation of the report, click here for Multiple System Atrophy Epidemiology Insights @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple System Atrophy Emerging Drugs

• Ampreloxetine (TD-9855): Theravance Biopharma
Ampreloxetine is an investigational, once-daily Norepinephrine Reuptake Inhibitor (NRI) in development for treating patients with symptomatic neurogenic orthostatic hypotension (nOH). It has a high affinity for binding to norepinephrine transporters. By blocking the action of these transporters, ampreloxetine causes an increase in extracellular concentrations of norepinephrine.

Multiple System Atrophy Market Outlook
Currently, no disease-modifying agent is approved. The drug used to treat PD (parkinsonism), most notably levodopa (SINEMET), is also prescribed for MSA individuals. However, the efficacy of such medications varies greatly among affected individuals. Apart from levodopa, other drugs used to treat PD may be used to treat MSA individuals. These include dopamine agonists such as ropinirole (Requip) and pramipexole (Mirapexin), which increase the activity of dopamine receptors in the brain. This helps the brain receive dopamine signals. Midodrine hydrochloride (ProAmatine) has been used to treat low blood pressure, sometimes associated with MSA. Adrenergic drugs such as ephedrine may be used to treat low blood pressure. L-threo-dihydroxyphenylserine (L-DOPS or L-threo-DOPS) can also treat low blood pressure.

Multiple System Atrophy Treatment Market
The approved multiple system atrophy market segment includes NORTHERA (droxidopa), the world's first approved therapy for symptomatic nOH. Dainippon Sumitomo Pharma (DSP) developed it and commercialized it in Japan in 1989. DSP sold the drug license to Chelsea Therapeutics International in 2006. Chelsea received accelerated approval for NORTHERA from the US FDA in February 2014 for symptomatic benefit in adult patients with nOH, and exclusivity will expire in February 2021. nOH is found in approximately 66-90% of MSA patients and is a major cause of disability and injury in the disease.

Browse More Related Reports of the Multiple System Atrophy Market Research Reports, click here for Multiple System Atrophy Market Forecast @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Multiple System Atrophy Market Research Report

• Coverage- 7MM

• Multiple System Atrophy Companies- H Lundbeck A/S, Theravance Biopharma, Brain Neurotherapy Bio, Inc., Jonis Pharmaceuticals, Inc., Alterity Therapeutics, and others.

• Multiple System Atrophy Pipeline Therapies- Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, and others.

• Multiple System Atrophy Market Dynamics: Multiple System Atrophy Market Drivers and Barriers

Read the Full Research Report of the Multiple System Atrophy Market Forecast Report, click here for Multiple System Atrophy Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Multiple System Atrophy Market Overview at a Glance
4. Multiple System Atrophy Market: Future Perspective
5. Executive Summary of Multiple System Atrophy (MSA)
6. Key Events
7. Disease Background and Overview: Multiple System Atrophy (MSA)
8. Epidemiology and Patient Population
9. Patient Journey
10. Emerging Drugs
11. Multiple System Atrophy (MSA): Seven Major Market Analysis
12. Key Opinion Leaders' View
13. Market Drivers
14. Market Barriers
15. SWOT Analysis
16. Unmet Needs
17. Reimbursement and Market Access
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Consult with our Business Expert regarding "Multiple System Atrophy Market Landscape" @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Trending Market Reports in 2023

Healthcare Partner Identification Services @ https://www.delveinsight.com/consulting/partner-identification-services

Medical Marijuana Market @ https://www.delveinsight.com/report-store/medical-marijuana-market-insight

Oncolytic Virus Cancer Therapy Pipeline @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Overactive Bladder Syndrome Market @ https://www.delveinsight.com/report-store/overactive-bladder-market

Pediatric Growth Hormone Deficiency PGHD Market @ https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market

Percutaneous Arterial Closure Device Market @ https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market

Ranibizumab Biosimilars Insight @ https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight

Schistosomiasis Market @ https://www.delveinsight.com/report-store/schistosomiasis-market

Stem Cell Market @ https://www.delveinsight.com/report-store/stem-cell-market

Superficial Punctate Keratitis Market @ https://www.delveinsight.com/report-store/superficial-punctate-keratitis-market

Technical Due Diligence @ https://www.delveinsight.com/consulting/due-diligence-services

Transient Ischemic Attack Market @ https://www.delveinsight.com/report-store/transient-ischemic-attack-market

Wilms Tumor Market @ https://www.delveinsight.com/report-store/wilms-tumor-market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.